JPH07119208B2 - Naphthylthioalkylcarboxylic acid derivatives - Google Patents
Naphthylthioalkylcarboxylic acid derivativesInfo
- Publication number
- JPH07119208B2 JPH07119208B2 JP21189290A JP21189290A JPH07119208B2 JP H07119208 B2 JPH07119208 B2 JP H07119208B2 JP 21189290 A JP21189290 A JP 21189290A JP 21189290 A JP21189290 A JP 21189290A JP H07119208 B2 JPH07119208 B2 JP H07119208B2
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- naphthylthioalkylcarboxylic
- group
- general formula
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 title claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- -1 alkali metal salt Chemical group 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 206010033645 Pancreatitis Diseases 0.000 description 5
- 206010033647 Pancreatitis acute Diseases 0.000 description 5
- 201000003229 acute pancreatitis Diseases 0.000 description 5
- 208000003770 biliary dyskinesia Diseases 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 4
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- VNZCGKFICBBJQF-UHFFFAOYSA-N 2-(naphthalen-2-ylsulfanylmethyl)pentanedinitrile Chemical compound C1=CC=CC2=CC(SCC(CCC#N)C#N)=CC=C21 VNZCGKFICBBJQF-UHFFFAOYSA-N 0.000 description 2
- NPZLUDUFVKRONY-UHFFFAOYSA-N 2-(naphthalen-2-ylsulfanylmethyl)pentanedioic acid Chemical compound C1=CC=CC2=CC(SCC(CCC(=O)O)C(O)=O)=CC=C21 NPZLUDUFVKRONY-UHFFFAOYSA-N 0.000 description 2
- RFCQDOVPMUSZMN-UHFFFAOYSA-N 2-Naphthalenethiol Chemical compound C1=CC=CC2=CC(S)=CC=C21 RFCQDOVPMUSZMN-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- BYEHXOQMITZHNP-UHFFFAOYSA-N 5-methoxy-2-(naphthalen-2-ylsulfanylmethyl)-5-oxopentanoic acid Chemical compound C1=CC=CC2=CC(SCC(CCC(=O)OC)C(O)=O)=CC=C21 BYEHXOQMITZHNP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- IYWJINJTWGAVAQ-UHFFFAOYSA-N methyl 5-[bis(2-cyclohexylethyl)amino]-4-(naphthalen-2-ylsulfonylmethyl)-5-oxopentanoate Chemical compound C=1C=C2C=CC=CC2=CC=1S(=O)(=O)CC(CCC(=O)OC)C(=O)N(CCC1CCCCC1)CCC1CCCCC1 IYWJINJTWGAVAQ-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- FMMYWCDTBMIIPS-UHFFFAOYSA-N 2-cyclohexyl-n-(2-cyclohexylethyl)ethanamine Chemical compound C1CCCCC1CCNCCC1CCCCC1 FMMYWCDTBMIIPS-UHFFFAOYSA-N 0.000 description 1
- NGCJVMZXRCLPRQ-UHFFFAOYSA-N 2-methylidenepentanedinitrile Chemical compound N#CC(=C)CCC#N NGCJVMZXRCLPRQ-UHFFFAOYSA-N 0.000 description 1
- 229940122623 CCK receptor antagonist Drugs 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical group C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は医薬品の製造中間体として有用な、一般式 (式中のR1、R2は同じでも異なっていてもよくそれぞれ
炭素数3〜6のシクロアルキル基、炭素数2〜5のアシ
ロキシ基、炭素数2〜7のアルコキシカルボニル基、炭
素数3〜6のアルケニルオキシ基または炭素数1〜6の
アルコキシ基であり、R3は炭素数1〜4のアルキル基ま
たはベンジル基であり、mおよびnは1、2または3で
ある)で表されるナフチルチオアルキルカルボン酸誘導
体に関するものである。TECHNICAL FIELD The present invention relates to a general formula useful as an intermediate for the manufacture of pharmaceuticals. (R 1 and R 2 in the formula may be the same or different and each is a cycloalkyl group having 3 to 6 carbon atoms, an acyloxy group having 2 to 5 carbon atoms, an alkoxycarbonyl group having 2 to 7 carbon atoms, and 3 carbon atoms. Is an alkenyloxy group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms, R 3 is an alkyl group having 1 to 4 carbon atoms or a benzyl group, and m and n are 1, 2 or 3) And a naphthylthioalkylcarboxylic acid derivative.
さらに詳しく述べれば、本発明は、コレシストキニン
(cholecystokinin、以下CCKという)受容体拮抗作用を
示し、過敏性大腸炎、胆道ジスキネジー、急性膵炎など
の疾患の予防および治療剤として有用な、一般式 (式中のR4は水素原子、炭素数1〜4のアルキル基また
はベンジル基であり、R1、R2mおよびnは前記と同じ意
味をもつ)で表されるナフチルスルホニルアルキルカル
ボン酸誘導体の製造中間体として有用な一般式(I)で
表されるナフチルチオアルキルカルボン酸誘導体に関す
るものである。More specifically, the present invention shows a cholecystokinin (hereinafter referred to as CCK) receptor antagonistic action, and is useful as a prophylactic and therapeutic agent for diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis. (In the formula, R 4 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a benzyl group, and R 1 , R 2 m and n have the same meanings as described above), and a naphthylsulfonylalkylcarboxylic acid derivative The present invention relates to a naphthylthioalkylcarboxylic acid derivative represented by the general formula (I), which is useful as an intermediate for the production of
従来の技術 CCKはガストリン(gastrin)、セクレチン(secretin)
と並ぶ代表的な消化管ホルモンで、特に膵外分泌刺激、
胆嚢収縮等に関与するホルモンであることが知られてい
る。Conventional technology CCK is gastrin, secretin
It is a typical gastrointestinal hormone along with, especially pancreatic exocrine stimulation,
It is known to be a hormone involved in gallbladder contraction and the like.
近年、CCKに関する研究が進められ、各種疾患におけるC
CKの関与について解明されてきた。In recent years, research on CCK has been advanced, and C
The involvement of CK has been elucidated.
その結果、特異的、競合的かつ可逆的なCCK受容体拮抗
剤が過敏性大腸炎、胆道ジスキネジー、急性膵炎などの
疾患の予防および治療剤として期待されるようになり、
注目を集めている。As a result, specific, competitive and reversible CCK receptor antagonists have come to be expected as preventive and therapeutic agents for diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis,
It is getting attention.
発明が解決しようとする課題 本発明の目的は、CCK受容体拮抗作用を有し、過敏性大
腸炎、胆道ジスキネジー、急性膵炎などの疾患の予防お
よび治療剤として有用な前記一般式(II)で表されるナ
フチルスルホニルアルキルカルボン酸誘導体の製造中間
体として有用な前記一般式(I)で表されるナフチルチ
オアルキルカルボン酸誘導体を提供することである。The object of the present invention is to have a CCK receptor antagonistic action, in the general formula (II) useful as a prophylactic and therapeutic agent for diseases such as irritable colitis, biliary dyskinesia, acute pancreatitis and the like. It is to provide a naphthylthioalkylcarboxylic acid derivative represented by the general formula (I), which is useful as an intermediate for the production of the naphthylsulfonylalkylcarboxylic acid derivative represented.
課題を解決するための手段 前記一般式(II)で表されるナフチルスルホニルアルキ
ルカルボン酸誘導体は強力なCCK受容体拮抗作用を有
し、過敏性大腸炎、胆道ジスキネジー、急性膵炎などの
疾患の予防および治療剤として有用である。Means for Solving the Problems The naphthylsulfonylalkylcarboxylic acid derivative represented by the general formula (II) has a strong CCK receptor antagonistic action, and prevents diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis. And is useful as a therapeutic agent.
本発明の前記一般式(I)で表されるナフチルチオアル
キルカルボン酸誘導体は、これを適当な酸化剤で酸化
し、必要に応じ加水分解あるいは加水素分解することに
より、きわめて容易に収率よく前記一般式(II)の化合
物に導くことができる。The naphthylthioalkylcarboxylic acid derivative represented by the above general formula (I) of the present invention is very easily and in good yield by oxidizing the naphthylthioalkylcarboxylic acid derivative with an appropriate oxidizing agent and hydrolyzing or hydrogenolyzing it as necessary. The compounds of the general formula (II) can be derived.
本発明の一般式(I)で表されるナフチルチオアルキル
カルボン酸誘導体は新規な化合物であり、以下のように
して製造することができる。The naphthylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention is a novel compound and can be produced as follows.
すなわち、一般式 (式中のR3は前記と同じ意味をもつ)で表されるナフチ
ルチオアルキルカルボン酸誘導体またはその反応性官能
目的誘導体と、一般式 (式中のR1、R2m、およびnは前記と同じ意味をもつ)
で表されるアミン類とを反応させることにより製造する
ことができる。That is, the general formula A naphthylthioalkylcarboxylic acid derivative represented by the formula (R 3 has the same meaning as described above) or a reactive functional object derivative thereof, and a general formula (R 1 , R 2 m, and n in the formula have the same meanings as described above)
It can be produced by reacting with an amine represented by
本発明の一般式(I)の化合物の製造方法において出発
原料として用いられる前記一般式(III)の化合物は新
規化合物であり、以下のようにして製造することができ
る。The compound of the general formula (III) used as a starting material in the method for producing the compound of the general formula (I) of the present invention is a novel compound and can be produced as follows.
すなわち、式 で表される2−ナフタレンチオールと、一般式 (式中のAおよびBはそれぞれシアノ基または炭素数2
〜5のアルコキシカルボニル基であるかあるいはAが炭
素数2〜5のアルコキシカルボニル基でBがカルボキシ
基またはそのアルカリ金属塩である)で表される化合物
とをルイス塩基またはルイス酸触媒の存在下に反応し
て、一般式 (式中のAおよびBは前記と同じ意味をもつ)で表され
る化合物を製し、必要に応じこれを適当な方法により加
水分解、モノエステル化を行うことにより得ることがで
きる。That is, the formula 2-naphthalenethiol represented by (A and B in the formula are each a cyano group or a carbon number of 2
A compound represented by the formula (1) to (5) or (A is an alkoxycarbonyl group having 2 to 5 carbon atoms and B is a carboxy group or an alkali metal salt thereof) in the presence of a Lewis base or a Lewis acid catalyst. In response to the general formula (A and B in the formula have the same meanings as described above), and can be obtained by hydrolysis and monoesterification by a suitable method, if necessary.
本発明の一般式(I)で表されるナフチルチオアルキル
カルボン酸誘導体は不斉炭素を有しており、2種の光学
異性体が存在するが、本発明においてはR体、S体また
はその混合物のいずれも含まれる。The naphthylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention has an asymmetric carbon and has two kinds of optical isomers. Any mixture is included.
発明の効果 本発明の一般式(I)で表されるナフチルチオアルキル
カルボン酸誘導体は、適当な酸化剤、例えば、m−クロ
ロ過安息香酸を用いて酸化し、必要に応じて加水分解あ
るいは加水素分解することにより極めて容易に、収率よ
く一般式(II)で表されるナフチルスルホニルアルキル
カルボン酸誘導体に導くことができる。EFFECTS OF THE INVENTION The naphthylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention is oxidized by using an appropriate oxidizing agent such as m-chloroperbenzoic acid, and is hydrolyzed or added as required. By hydrogenolysis, the naphthylsulfonylalkylcarboxylic acid derivative represented by the general formula (II) can be extremely easily and efficiently obtained.
このようにして、本発明の一般式(I)の化合物から製
造される一般式(II)で表される化合物はCCK受容体拮
抗作用を有し、過敏性大腸炎、胆道ジスキネジー、急性
膵炎などの疾患治療剤として有用である。As described above, the compound represented by the general formula (II) produced from the compound of the general formula (I) of the present invention has a CCK receptor antagonistic action, and is susceptible to irritable colitis, biliary dyskinesia, acute pancreatitis, etc. It is useful as a therapeutic agent for the disease.
例えば、125IでラベルしたCCK−8を用いたラット摘出
膵臓のCCK受容体に対するバインディングアッセイにお
いて、4−〔N,N−(2−シクロヘキシルエチル)カル
バモイル〕−5−(2−ナフチルスルホニル)ペンタン
酸は、1.1×10-7モル濃度で50%結合抑制(IC50)を示
す。For example, in a binding assay for CCK receptor in rat isolated pancreas using 125 I-labeled CCK-8, 4- [N, N- (2-cyclohexylethyl) carbamoyl] -5- (2-naphthylsulfonyl) pentane was obtained. The acid exhibits 50% binding inhibition (IC 50 ) at 1.1 × 10 −7 molarity.
実施例 本発明の内容を以下の参考例および実施例でさらに詳細
に説明する。なお、各参考例および実施例中の化合物の
融点はすべて未補正である。EXAMPLES The contents of the present invention will be described in more detail with reference to the following reference examples and examples. The melting points of the compounds in Reference Examples and Examples are all uncorrected.
参考例1 4−メトキシカルボニル−2−(2−ナフチルチオメチ
ル)酪酸 2−ナフタレンチオール10.0gと2−メチレングルタロ
ニトリル6.8mlをエタノール150mlに溶かし、トリトンB
(40%メタノール溶液)10滴を加えたのち2時間加熱還
流させた。反応液を減圧下に濃縮後、クロロホルムで抽
出し水洗したのち無水硫酸マグネシウムで乾燥した。減
圧下に溶媒を留去後、残留物を酢酸エチル−ヘキサンよ
り再結晶し、融点52〜55℃の2−(2−ナフチルチオメ
チル)グルタロニトリル15.6gを得た。Reference Example 1 4-Methoxycarbonyl-2- (2-naphthylthiomethyl) butyric acid 10.0 g of 2-naphthalenethiol and 6.8 ml of 2-methyleneglutaronitrile were dissolved in 150 ml of ethanol, and Triton B was added.
After adding 10 drops (40% methanol solution), the mixture was heated under reflux for 2 hours. The reaction mixture was concentrated under reduced pressure, extracted with chloroform, washed with water, and dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was recrystallized from ethyl acetate-hexane to obtain 15.6 g of 2- (2-naphthylthiomethyl) glutaronitrile having a melting point of 52 to 55 ° C.
元素分析値:(C16H14N2Sとして) C% H% N% 計算値 72.15 5.30 10.52 実測値 71.98 5.24 10.41 IR(KBr):νCN2245cm-1 NMR(CDC13) δ:1.95〜2.3(2H,m),2.4〜2.7(2H,m),2.8〜2.95
(1H,m),3.13(1H,dd,J=7.1,13.7Hz),3.30(1H,dd,J
=6.6,13.7Hz),7.4〜7.6(3H,m),7.75〜8.0(4H,m) 2−(2−ナフチルチオメチル)グルタロニトリル15.5
gを酢酸70mlに溶かし、濃塩酸70mlを加え17時間加熱還
流させた。反応液を減圧下に濃縮し,ジエチルエーテル
を加え不溶物をろ去後、水洗いしたのち炭酸水素ナトリ
ウム水溶液を加え振り混ぜた。水層を塩酸で酸性とした
のち、ジエチルエーテルで抽出し,水洗後無水硫酸マグ
ネシウムで乾燥した。減圧下に溶媒を留去後、残留物を
ジエチルエーテル−ヘキサンより再結晶し、融点140〜1
42℃の2−(2−ナフチルチオメチル)グルタル酸15.9
gを得た。Elemental analysis value: (as C 16 H 14 N 2 S) C% H% N% Calculated value 72.15 5.30 10.52 Measured value 71.98 5.24 10.41 IR (KBr): ν CN 2245cm −1 NMR (CDC 1 3 ) δ: 1.95 to 2.3 (2H, m), 2.4 ~ 2.7 (2H, m), 2.8 ~ 2.95
(1H, m), 3.13 (1H, dd, J = 7.1,13.7Hz), 3.30 (1H, dd, J
= 6.6,13.7Hz), 7.4 ~ 7.6 (3H, m), 7.75 ~ 8.0 (4H, m) 2- (2-naphthylthiomethyl) glutaronitrile 15.5
g was dissolved in 70 ml of acetic acid, 70 ml of concentrated hydrochloric acid was added, and the mixture was heated under reflux for 17 hours. The reaction solution was concentrated under reduced pressure, diethyl ether was added, insoluble materials were removed by filtration, washed with water, then an aqueous sodium hydrogen carbonate solution was added, and the mixture was shaken. The aqueous layer was acidified with hydrochloric acid, extracted with diethyl ether, washed with water and dried over anhydrous magnesium sulfate. After distilling off the solvent under reduced pressure, the residue was recrystallized from diethyl ether-hexane to give a melting point of 140-1.
42 ° C 2- (2-naphthylthiomethyl) glutaric acid 15.9
got g.
元素分析値:(C16H16O4Sとして) C% H% 計算値 63.14 5.30 実測値 63.37 5.34 IR(KBr):νC=O1720cm-1 NMR(DMS0−d6) δ:1.7〜2.0(2H,m),2.15〜2.4(2H,m),2.5〜2.65
(1H,m),3.1〜3.4(2H,m),7.35〜7.6(3H,m),7.75〜
8.0(4H,m),12.32(2H,s) 2−(2−ナフチルチオメチル)グルタル酸28.8gをメ
タノール300mlに溶かし、p−トルエンスルホン酸0.9g
を加え40℃で撹拌下に2.5時間反応させた。反応液を減
圧下に濃縮後、残留物に水を加え酢酸エチルで抽出し水
洗後無水硫酸マグネシウムで乾燥した。減圧下に溶媒を
留去後、残留物をイソプロピルエーテルより再結晶し、
融点70〜71℃の4−メトキシカルボニル−2−(2−ナ
フチルチオメチル)酪酸27.4gを得た。Elemental analysis value: (as C 16 H 16 O 4 S) C% H% Calculated value 63.14 5.30 Measured value 63.37 5.34 IR (KBr): ν C = O 1720 cm -1 NMR (DMS0-d 6 ) δ: 1.7 to 2.0 (2H, m), 2.15 ~ 2.4 (2H, m), 2.5 ~ 2.65
(1H, m), 3.1 ~ 3.4 (2H, m), 7.35 ~ 7.6 (3H, m), 7.75 ~
8.0 (4H, m), 12.32 (2H, s) 2- (2-naphthylthiomethyl) glutaric acid 28.8 g was dissolved in 300 ml of methanol to give p-toluenesulfonic acid 0.9 g.
Was added and reacted at 40 ° C. for 2.5 hours with stirring. The reaction mixture was concentrated under reduced pressure, water was added to the residue, the mixture was extracted with ethyl acetate, washed with water, and dried over anhydrous magnesium sulfate. After distilling off the solvent under reduced pressure, the residue was recrystallized from isopropyl ether,
27.4 g of 4-methoxycarbonyl-2- (2-naphthylthiomethyl) butyric acid having a melting point of 70 to 71 ° C. was obtained.
元素分析値:(C17H18O4Sとして) C% H% 計算値 64.13 5.70 実測値 64.11 5.50 IR(KBr):νC=01730,1700cm-1 NMR(CDC13) δ:1.95〜2.2(2H,m),2.3〜2.5(2H,m),2.65〜2.8
(1H,m),3.10(1H,dd,J=6.6,13.2Hz),3.33(1H,dd,J
=7.7,13.2Hz),3.62(3H,s),7.4〜7.55(3H,m),7.7
〜7.9(4H,m) 参考例2 4−ベンジルオキシカルボニル−2−(2−ナフチルチ
オメチル)酪酸 2−(2−ナフチルチオメチル)グルタル酸14.0gをア
セトニトリル180mlに溶かし、ベンジルアルコール57ml
およびp−トルエンスルホン酸0.52gを加え23時間加熱
還流させた。反応液を減圧下に濃縮し、残留物をシリカ
ゲルフラッシュカラムクロマトグラフィー(溶出溶媒:
塩化メチレン/メタノール=70/1)で精製後、酢酸エチ
ル−ヘキサンより再結晶し、融点94〜95℃の4−ベンジ
ルオキシカルボニル−2−(2−ナフチルチオメチル)
酪酸11.0gを得た。Elemental analysis value: (as C 17 H 18 O 4 S) C% H% Calculated value 64.13 5.70 Measured value 64.11 5.50 IR (KBr): ν C = 0 1730,1700 cm −1 NMR (CDC 1 3 ) δ: 1.95 to 2.2 (2H, m), 2.3 ~ 2.5 (2H, m), 2.65 ~ 2.8
(1H, m), 3.10 (1H, dd, J = 6.6, 13.2Hz), 3.33 (1H, dd, J
= 7.7, 13.2Hz), 3.62 (3H, s), 7.4 to 7.55 (3H, m), 7.7
-7.9 (4H, m) Reference Example 2 4-benzyloxycarbonyl-2- (2-naphthylthiomethyl) butyric acid 2- (2-naphthylthiomethyl) glutaric acid 14.0 g was dissolved in 180 ml of acetonitrile, and 57 ml of benzyl alcohol was added.
And 0.52 g of p-toluenesulfonic acid were added, and the mixture was heated under reflux for 23 hours. The reaction solution was concentrated under reduced pressure, and the residue was subjected to silica gel flash column chromatography (elution solvent:
After purification with methylene chloride / methanol = 70/1), recrystallization from ethyl acetate-hexane gave 4-benzyloxycarbonyl-2- (2-naphthylthiomethyl), melting point 94-95 ° C.
11.0 g of butyric acid was obtained.
元素分析値:(C23H22O4Sとして) C% H% 計算値 70.03 5.62 実測値 70.05 5.69 IR(KBr):νC=01730,1700cm-1 NMR(CDC13) δ:1.9〜2.2(2H,m),2.3〜2.55(2H,m),2.65〜2.8
(1H,m),3.09(1H,dd,J=6.6,13.2Hz),3.26(1H,dd,J
=7.7,13.2Hz),5.09(2H,s),7.2〜7.5(8H,m),7.65
〜7.85(4H,m) 実施例1 4−〔N,N−ビス−(2−シクロヘキシルエチル)カル
バモイル〕−5−(2−ナフチルチオ)ペンタン酸メチ
ル 4−メトキシカルボニル−2−(2−ナフチルチオメチ
ル)酪酸0.64gを乾燥塩化メチレン10mlに溶かし、塩化
チオニル0.3mlを加え2時間加熱還流させた。反応液を
減圧下に濃縮乾固定し油状の残留物を得た。この残留物
の乾燥塩化メチレン5ml溶液を、ビス−(2−シクロヘ
キシルエチル)アミン0.48gおよびトリエチルアミン0.7
mlの乾燥塩化メチレン15ml溶液に、氷冷撹拌下に滴下し
たのち、室温で20時間反応させた。反応液を希塩酸、炭
酸水素ナトリウム水溶液および水で順次洗ったのち無水
硫酸マグネシウムで乾燥した。減圧下に溶剤を留去後、
残留物をシリカゲル中圧液体カラムクロマトグラフィー
(溶出溶媒:酢酸エチル/ヘキサン=1/2)で精製し、
油状の4−〔N,N−ビス−(2−シクロヘキシルエチ
ル)カルバモイル〕−5−(2−ナフチルチオ)ペンタ
ン酸メチル0.94gを得た。Elemental analysis value: (as C 23 H 22 O 4 S) C% H% Calculated value 70.03 5.62 Measured value 70.05 5.69 IR (KBr): ν C = 0 1730,1700 cm −1 NMR (CDC1 3 ) δ: 1.9 to 2.2 (2H, m), 2.3 ~ 2.55 (2H, m), 2.65 ~ 2.8
(1H, m), 3.09 (1H, dd, J = 6.6, 13.2Hz), 3.26 (1H, dd, J
= 7.7, 13.2Hz), 5.09 (2H, s), 7.2 to 7.5 (8H, m), 7.65
-7.85 (4H, m) Example 1 Methyl 4- [N, N-bis- (2-cyclohexylethyl) carbamoyl] -5- (2-naphthylthio) pentanoate 4-methoxycarbonyl-2- (2-naphthylthio) 0.64 g of methyl) butyric acid was dissolved in 10 ml of dry methylene chloride, 0.3 ml of thionyl chloride was added, and the mixture was heated under reflux for 2 hours. The reaction solution was concentrated and dried under reduced pressure to obtain an oily residue. A solution of this residue in 5 ml of dry methylene chloride was added to 0.48 g of bis- (2-cyclohexylethyl) amine and 0.7 of triethylamine.
After adding dropwise to a solution of 15 ml of dry methylene chloride in 15 ml of ice-cooled solution, the mixture was reacted at room temperature for 20 hours. The reaction solution was washed successively with diluted hydrochloric acid, an aqueous solution of sodium hydrogen carbonate and water, and then dried over anhydrous magnesium sulfate. After distilling off the solvent under reduced pressure,
The residue was purified by silica gel medium pressure liquid column chromatography (eluting solvent: ethyl acetate / hexane = 1/2),
0.94 g of oily methyl 4- [N, N-bis- (2-cyclohexylethyl) carbamoyl] -5- (2-naphthylthio) pentanoate was obtained.
IR(neat):νC=01735,1635cm-1 NMR(CDC13) δ:0.3〜1.75(26H,m),2.0〜2.5(4H,m),2.85〜3.4
(7H,m),3.65(3H,s),7.35〜7.55(3H,m),7.7〜7.85
(4H,m) 実施例2 実施例1と同様にして表の化合物(油状)を製造した。 IR (neat): ν C = 0 1735,1635cm -1 NMR (CDC1 3) δ: 0.3~1.75 (26H, m), 2.0~2.5 (4H, m), 2.85~3.4
(7H, m), 3.65 (3H, s), 7.35 ~ 7.55 (3H, m), 7.7 ~ 7.85
(4H, m) Example 2 In the same manner as in Example 1, the compounds in the table (oil) were produced.
参考例3 4−〔N,N−ビス−(2−シクロヘキシルエチル)カル
バモイル〕−5−(2−ナフチルスルホニル)ペンタン
酸メチルおよび4−〔N,N−ビス−(2−シクロヘキシ
ルエチル)カルバモイル〕−5−(2−ナフチルスルホ
ニル)ペンタン酸 4−〔N,N−ビス−(2−シクロヘキシルエチル)カル
バモイル〕−5−(2−ナフチルチオ)ペンタン酸メチ
ル0.50gを乾燥塩化メチレン20mlに溶かし、氷冷撹拌下
にm−クロロ過安息香酸(80%)0.51gを少量ずつ加え
たのち、室温で6時間反応させた。反応液に亜硫酸ナト
リウムを加えたのち、炭酸水素ナトリウム水溶液および
水で順次洗い無水硫酸マグネシウムで乾燥した。減圧下
に溶媒を留去し、残留物をシリカゲル中圧液体カラムク
ロマトグラフィー(溶出溶媒:酢酸エチル/ヘキサン=
1/2)で精製後、酢酸エチル−ヘキサンより再結晶し、
融点115.5〜118℃の4−〔N,N−ビス(2−シクロヘキ
シルエチル)カルバモイル〕−5−(2−ナフチルスル
ホニル)ペンタン酸メチル0.48gを得た。 Reference Example 3 Methyl 4- [N, N-bis- (2-cyclohexylethyl) carbamoyl] -5- (2-naphthylsulfonyl) pentanoate and 4- [N, N-bis- (2-cyclohexylethyl) carbamoyl] Methyl 5- (2-naphthylsulfonyl) pentanoic acid 4- [N, N-bis- (2-cyclohexylethyl) carbamoyl] -5- (2-naphthylthio) pentanoate 0.50 g was dissolved in 20 ml of dry methylene chloride and iced. 0.51 g of m-chloroperbenzoic acid (80%) was added little by little with stirring under cold conditions, and the mixture was reacted at room temperature for 6 hours. After adding sodium sulfite to the reaction solution, it was washed successively with an aqueous solution of sodium hydrogen carbonate and water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was subjected to silica gel medium pressure liquid column chromatography (eluting solvent: ethyl acetate / hexane =
After purification with 1/2), recrystallized from ethyl acetate-hexane,
0.48 g of methyl 4- [N, N-bis (2-cyclohexylethyl) carbamoyl] -5- (2-naphthylsulfonyl) pentanoate having a melting point of 115.5 to 118 ° C. was obtained.
元素分析値:(C33H47NO5Sとして) C% H% N% 計算値 69.56 8.31 2.46 実測値 69.51 8.22 2.33 NMR(CDC13) δ:0.75〜2.1(28H,m),2.32(2H,t,J=7.1Hz),2.95
〜3.45(6H,m),3.63(3H,s),3.84(1H,dd,J=7.7,13.
7Hz),7.55〜7.75(2H,m),7.8〜8.1(4H,m),8.48(1
H,s) 4−〔N,N−ビス−(2−シクロヘキシルエチル)カル
バモイル〕−5−(2−ナフチルスルホニル)ペンタン
酸メチル150mgをエタノール3mlに溶かし、1規定水酸化
ナリウム水溶液0.26mlを加え室温で16時間撹拌した。反
応液を減圧下に濃縮後、希塩酸で酸性としたのち酢酸エ
チルで抽出し、水洗後無水硫酸マグネシウムで乾燥し
た。減圧下に溶媒を留去後、残留物を酢酸エチル−ヘキ
サンより再結晶し、融点138.5〜139.5℃の4−〔N,N−
ビス−(2−シクロヘキシルエチル)カルバモイル〕−
5−(2−ナフチルスルホニル)ペンタン酸86mgを得
た。Elemental analysis value: (as C 33 H 47 NO 5 S) C% H% N% Calculated value 69.56 8.31 2.46 Measured value 69.51 8.22 2.33 NMR (CDC1 3 ) δ: 0.75 to 2.1 (28H, m), 2.32 (2H, t, J = 7.1Hz), 2.95
~ 3.45 (6H, m), 3.63 (3H, s), 3.84 (1H, dd, J = 7.7,13.
7Hz), 7.55 ~ 7.75 (2H, m), 7.8 ~ 8.1 (4H, m), 8.48 (1
H, s) 4- [N, N-bis- (2-cyclohexylethyl) carbamoyl] -5- (2-naphthylsulfonyl) pentanoate (150 mg) was dissolved in ethanol (3 ml), and 1N aqueous sodium hydroxide solution (0.26 ml) was added. Stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, acidified with diluted hydrochloric acid, extracted with ethyl acetate, washed with water, and dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was recrystallized from ethyl acetate-hexane to give 4- [N, N-melting point 138.5-139.5 ° C.
Bis- (2-cyclohexylethyl) carbamoyl]-
86 mg of 5- (2-naphthylsulfonyl) pentanoic acid was obtained.
元素分析値:(C32H45NO5Sとして) C% H% N% 計算値 69.16 8.16 2.52 実測値 69.22 8.28 2.48 NMR(CDC13) δ:0.75〜2.1(28H,m),2.37(2H,t,J=7.1Hz),3.0
〜3.35(6H,m),3.83(1H,dd,J=7.7,13.7Hz),7.55〜
7.75(2H,m),7.8〜8.05(4H,m),8.48(1H,s)Elemental analysis value: (as C 32 H 45 NO 5 S) C% H% N% Calculated value 69.16 8.16 2.52 Measured value 69.22 8.28 2.48 NMR (CDC1 3 ) δ: 0.75 to 2.1 (28H, m), 2.37 (2H, t, J = 7.1Hz), 3.0
~ 3.35 (6H, m), 3.83 (1H, dd, J = 7.7, 13.7Hz), 7.55 ~
7.75 (2H, m), 7.8 ~ 8.05 (4H, m), 8.48 (1H, s)
───────────────────────────────────────────────────── フロントページの続き (72)発明者 阪 正昭 長野県松本市野溝木工1―2―34 キッセ イ薬品第二青友寮 (72)発明者 小林 通洋 長野県東筑摩郡明科町大字中川手3158番地 審査官 脇村 善一 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Masaaki Saka, Masaaki Saka 1-2-34 Nomizo Woodwork, Matsumoto-shi, Nagano Kissei Yakuhin Dairyo Dormitory (72) Inventor Toyohiro Kobayashi 3158 Nakagawate, Meishina-cho, Higashichikuma-gun, Nagano Prefecture Address Examiner Zenichi Wakimura
Claims (1)
炭素数3〜6のシクロアルキル基、炭素数2〜5のアシ
ロキシ基、炭素数2〜7のアルコキシカルボニル基、炭
素数3〜6のアルケニルオキシ基または炭素数1〜6の
アルコキシ基であり、R3は炭素数1〜4のアルキル基ま
たはベンジル基であり、mおよびnは1、2または3で
ある)で表されるナフチルチオアルキルカルボン酸誘導
体。1. A general formula (R 1 and R 2 in the formula may be the same or different and each is a cycloalkyl group having 3 to 6 carbon atoms, an acyloxy group having 2 to 5 carbon atoms, an alkoxycarbonyl group having 2 to 7 carbon atoms, and 3 carbon atoms. Is an alkenyloxy group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms, R 3 is an alkyl group having 1 to 4 carbon atoms or a benzyl group, and m and n are 1, 2 or 3) Naphthylthioalkylcarboxylic acid derivatives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21189290A JPH07119208B2 (en) | 1990-08-10 | 1990-08-10 | Naphthylthioalkylcarboxylic acid derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21189290A JPH07119208B2 (en) | 1990-08-10 | 1990-08-10 | Naphthylthioalkylcarboxylic acid derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0495063A JPH0495063A (en) | 1992-03-27 |
| JPH07119208B2 true JPH07119208B2 (en) | 1995-12-20 |
Family
ID=16613371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21189290A Expired - Lifetime JPH07119208B2 (en) | 1990-08-10 | 1990-08-10 | Naphthylthioalkylcarboxylic acid derivatives |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07119208B2 (en) |
-
1990
- 1990-08-10 JP JP21189290A patent/JPH07119208B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0495063A (en) | 1992-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS63139182A (en) | Production of thiazolidinedione derivative | |
| JPH08119968A (en) | Method for producing condensed pyridine compounds | |
| US20060135785A1 (en) | Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof | |
| CN1042934C (en) | Process for preparing 2-chloro-5-alkylaminomethylpyridines | |
| JPH07119208B2 (en) | Naphthylthioalkylcarboxylic acid derivatives | |
| JP2520777B2 (en) | Arylthioalkylcarboxylic acid derivatives | |
| JPH07119209B2 (en) | Naphthylthioalkylcarboxylic acid derivatives | |
| JPH07215952A (en) | Catechol derivative | |
| JP2520776B2 (en) | Naphthylthioalkylcarboxylic acid derivatives | |
| JPH07119205B2 (en) | Phenylthioalkylcarboxylic acid derivative | |
| JPH07119206B2 (en) | Dichlorophenylthioalkylcarboxylic acid derivative | |
| JPH07119207B2 (en) | Phenylthioalkylcarboxylic acid derivative | |
| KR100426534B1 (en) | An improved synthetic method of azelastine | |
| JP3233806B2 (en) | Method for producing sulfenylacetic acid derivative | |
| JP3288847B2 (en) | Method for producing 7-azaphthalide derivative | |
| JP2918136B2 (en) | 3-dialkylamino-2-substituted benzoyl acrylate compounds | |
| JPH0129793B2 (en) | ||
| JPH0436266A (en) | Phenylsulfinylalkylcarboxylic acid derivative | |
| JPH10265433A (en) | Method for producing phenylpropionic acid derivative | |
| JP2520318B2 (en) | Sulfonylalkylcarboxylic acid derivative | |
| JPH07119204B2 (en) | Phenylsulfinylalkylcarboxylic acid derivative | |
| JPH07119200B2 (en) | Naphthylsulfonylalkylcarboxylic acid derivatives | |
| JPH041736B2 (en) | ||
| JPH07119198B2 (en) | Phenylsulfonylalkylcarboxylic acid derivative | |
| JPH07119203B2 (en) | Phenylsulfinylalkylcarboxylic acid derivative |